Amy Han

Company: Regeneron Pharmaceuticals

Job title: Executive Director

Seminars:

Development of Selective TLR7 Agonist ADC for Tumor Localized Immunomodulation 5:30 pm

Discuss the design of a novel and selective TLR7 agonist Learn how Her2-TLR7a ADC activity requires Her2 and TLR7 targeting Explore how anti-HER2-TLR7a ADC induce robust, target dependent activation of the immune system leading to robust anti-tumor responses in vivoRead more

day: Day Two